Pricing Log in Create free account

bioAffinity Technologies, Inc. (BIAF) vs ProPhase Labs, Inc. (PRPH)

bioAffinity Technologies, Inc. and ProPhase Labs, Inc. are both Diagnostics & Research companies. bioAffinity Technologies, Inc. is the larger, with a market value of $5.1M against $1.2M — 4.3× the size. bioAffinity Technologies, Inc. grew revenue faster over the last twelve months: −23.2% against −43.5%. bioAffinity Technologies, Inc. has the higher net margin (−257.3% vs −717.4%) and the lower return on invested capital (−408.7% vs −387.3%). Across the 16 metrics below, bioAffinity Technologies, Inc. leads on 8 and ProPhase Labs, Inc. on 8.

Valuation

Metric BIAF PRPH Diagnostics & Research median
P/E n/m n/m 35.56
P/S 0.22 0.04 4.37
P/B 0.35 n/m 3.06
Price to free cash flow n/m n/m 35.76
EV/EBITDA 0.05 n/m 24.35
EV/Sales (0.10) 1.84 5.51
Earnings yield (2,934.19%) (23,896.00%) (1.89%)
Free cash flow yield (889.05%) (3,945.49%) (0.15%)

Profitability

Metric BIAF PRPH Diagnostics & Research median
Gross margin 34.61% 16.38% 50.89%
Operating margin (209.82%) (498.73%) (8.57%)
Net margin (257.33%) (717.43%) (6.37%)
Free cash flow margin (195.90%) (175.22%) 0.00%
Return on equity (1,860.15%) (543.95%) (2.92%)
Return on assets (245.51%) (45.53%) (6.71%)
Return on invested capital (408.67%) (387.30%) 0.00%

Growth

Metric BIAF PRPH Diagnostics & Research median
Revenue growth (TTM) (23.18%) (43.52%) 7.69%
EPS growth (last fiscal year) 61.55% 93.33% 25.92%
Revenue growth, 5-year CAGR — (21.43%) 7.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BIAF PRPH Diagnostics & Research median
Debt to equity 0.15 (1.82) 0.11
Current ratio 1.44 0.05 2.02
Net debt to EBITDA 0.57 (0.74) 0.70

Dividend

Metric BIAF PRPH Diagnostics & Research median
Dividend yield — — 0.66%
Payout ratio — — 0.20

Size

Metric BIAF PRPH Diagnostics & Research median
Market cap 5.08m 1.17m 2.16b

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack